References

  1. VIMIZIM [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2013.
  2. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36(2):293-307. doi:10.1007/s10545-013-9587-1.
  3. Data on file. BioMarin Pharmaceutical Inc.
  4. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54-61. doi:10.1016/j.ymgme.2013.01.021.
  5. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment: a special review. Curr Pharm Biotechnol. 2011;12(6):931-945. doi:1389-2010/11 $58.00+.00.
  6. Bank RA, Groener JEM, van Gemund JJ, et al. Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbations in cartilage of Morquio syndrome A patients. Mol Genet Metab. 2009;97(3):196-201. doi:10.1016/j.ymgme.2009.03.008.
  7. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20(1):9-22.
  8. Clarke LA, Winchester B, Giugliani R, et al. Biomarkers for the mucopolysaccharidoses: Discovery and clinical utility. Mol. Genet. Metab. 2012. doi:10.1016/j.ymgme.2012.05.003
  9. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996;19(3):357-365.
  10. McDonald A, Steiner R, Kuehl K, Turbeville S. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehab Med. 2010;119-127. doi:10.3233/PRM-2010-0114.
  11. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117. doi:10.1164/rccm.166/1/111.
  12. Beck M, Glössl J, Grubisic A, Spranger J. Heterogeneity of Morquio disease. Clin Genet. 1986;29(4):325-331.
  13. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165-174. doi:10.1007/s10545-007-0529-7.
  14. Palandurkar K, Thakur S, Agrawal U, Goyal MM, Basak A. The diagnosis of Morquio disease correlating the clinical, radiological and biochemical findings: a case series. J Clin Diagn Res. 2011;5(8):1641-1645.
  15. Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 2010;5(8):e12194. doi:10.1371/journal.pone.0012194.
  16. Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325. doi:10.1155/2012/471325.
  17. Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA (published online ahead of print February 23, 2012). J Inherit Metab Dis. doi:10.1007/s10545-012-9459-0.
  18. Fukuda S, Tomatsu S, Masue M, et al. Mucopolysaccharidosis type IVA: N-acetylgalactosamine-6-sulfate sulfatase exonic point mutations in classical Morquio and mild cases. J Clin Invest. 1992;90(3):1049-1053.
  19. Yeung AH, Cowan MJ, Horn B, Rosbe KW. Airway management in children with mucopolysaccharidoses. Arch Otolaryngol Head Neck Surg. 2009;135(1):73-79. doi:10.1001/archoto.2008.515.
  20. Ireland MA, Rowlands DB. Mucopolysaccharidosis type IV as a cause of mitral stenosis in an adult. Br Heart J. 1981;46(1):113-115.
  21. John RM, Hunter D, Swanton RH. Echocardiographic abnormalities in type IV mucopolysaccharidosis. Arch Dis Child. 1990;65(7):746-749.
  22. Pelley CJ, Kwo J, Hess DR. Tracheomalacia in an adult with respiratory failure and Morquio syndrome. Respir Care. 2007;52(3):278-282.
  23. Pritzker MR, King RA, Kronenberg RS. Upper airway obstruction during head flexion in Morquio’s disease. Am J Med. 1980;69(3):467-470.
  24. Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine. 1988;67(4):209-219.
  25. Gulati MS, Agin MA. Morquio syndrome: a rehabilitation perspective. J Spinal Cord Med. 1996;19(1):12-16. doi:10.1159/000202621.
  26. Holzgreve W, Gröbe H, von Figura K, Kresse H, Beck H, Mattei JF. Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients MPS IVB. Hum Genet. 1981;57(4):360-365.
  27. Danes BS. Corneal clouding in the genetic mucopolysaccharidoses: a cell culture study. Clin Genet. 1973;4(1):1-7.
  28. Couprie J, Denis P, Guffon N, Reynes N, Masset H, Beby F. Ocular manifestations in patients affected by Morquio syndrome (MPS IV). J Fr Ophtalmol. 2010;33(9):617-622. doi:10.1016/j.jfo.2010.09.008.
  29. Cahane M, Treister G, Abraham FA, Melamed S. Glaucoma in siblings with Morquio syndrome. Br J Ophthalmol. 1990;74(6):382-383.23Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA (published online ahead of print February 23, 2012). J Inherit Metab Dis. doi:10.1007/s10545-012-9459-0.
  30. Kinirons MJ, Nelson J. Dental findings in mucopolysaccharidosis type IV A (Morquio’s disease type A). Oral Surg Oral Med Oral Pathol. 1990;70(2):176-179.
  31. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007;150(4):395-399. doi:10.1016/j.jpeds.2006.12.052.
  32. Lehman TJ, Miller N, Norquist B, Underhill L, Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology. 2011;50 Suppl 5:v41-8.
  33. Tomatsu S, Fukuda S, Masue M, et al. Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase. Biochem Biophys Res Commun. 1991;181(2):677-683.